Haichen Pharmaceutical (300584.SZ): APIs for some products are actively exploring new processes, including using biofermentation to replace traditional chemical synthesis processes
Gelonghui May 9 丨 Some investors asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does the company have synthetic biotechnology-related technology reserves?” The company replied that the APIs for some of the company's products are actively exploring new processes, including using biological fermentation to replace traditional chemical synthesis processes to further reduce production costs and increase profit margins.
Haichen Pharmaceutical (300584.SZ) announced its 2023 annual results, with net profit of 363.15,600 yuan, an increase of 11.92% year-on-year
According to Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 518 million yuan, a year-on-year decrease of 1.64%; net profit attributable to shareholders of listed companies was 363.15,600 yuan, an increase of 11.92% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 369.653 million yuan, an increase of 17.51% over the previous year; the company plans to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.
Express News | Haichen Pharmaceutical: Liu Xiaoquan plans to reduce its shareholding by no more than 0.90225%
Liu Xiaoquan, the main shareholder of Haichen Pharmaceutical (300584.SZ), reduced its shares by 1%
Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the shareholder holding more than 5% of the company's shares, reduced its holdings by 1.2 million shares, accounting for 1.00% of the total share capital.
Haichen Pharmaceutical (300584.SZ): Products suitable for mycoplasma pneumonia are mainly injectable azithromycin
Gelonghui March 6 丨 An investor asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does your company have drugs for mycoplasma pneumonia?” The company replied that the company's products for mycoplasma pneumonia are mainly injectable azithromycin.
Haichen Pharmaceutical (300584.SZ): The main products are injectable landilol hydrochloride, torasemide for injections, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company
Gelonghui March 4 | Haichen Pharmaceutical (300584.SZ) said on the investor interactive platform that the company's main products, such as injectable landilol hydrochloride, injectable torasemide, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company. Among them, injectable landiolol hydrochloride is the exclusive first imitation in China. At the end of 2023, it once again entered the national medical insurance catalogue with a simple contract renewal method; rivaroxaban tablets and injectable tigecycline were selected for centralized drug procurement nationwide. Pharmaceutical R&D innovation has the characteristics of difficulty, long cycle time, and high investment. In the future, the company will integrate clinical needs, its own R&D capabilities, and market conditions
Haichen Pharmaceutical (300584.SZ) obtained the high-tech enterprise certificate
Gelonghui, January 16, 丨 Haichen Pharmaceutical (300584.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. The date of issue is November 6, 2023. The certificate number is GR202332007846, and the qualification is valid for three years.
Express News | Twenty listed companies, including Hengrui Pharmaceutical and China Resources Shuanghe, announced after the market that drugs entered the national health insurance catalogue, Junshi Biotech and Zhongsheng Pharmaceutical's COVID-19 drugs were included
Haichen Pharmaceutical (300584.SZ): Landilol hydrochloride for injections has been renewed and entered into the national health insurance catalogue
Haichen Pharmaceutical (300584.SZ) announced that the company successfully renewed the contract for injectable landilol hydrochloride and was included in the “National Base...
Haichen Pharmaceutical (300584.SZ): Landilol hydrochloride for injection passed generic drug consistency evaluation
Gelonghui, December 1丨Haichen Pharmaceutical (300584.SZ) announced that recently, the company received the “Drug Supplement Application Approval Notice” for injectable landilol hydrochloride approved and issued by the State Drug Administration. The product passed the generic drug quality and efficacy consistency evaluation. Injectable landilol hydrochloride is a novel ultra-short-acting adrenaline beta blocker. This type of drug plays an important and irreplaceable role in the treatment of tachyarrhythmia due to its rapid action, rapid metabolism, and rapid beta-blocking effect after discontinuation of the drug. Landiolol hydrochloride for injection is Europe's “2020 ESC/EACTS heart
Haichen Pharmaceutical (300584.SZ): Net profit of 2,947,500 yuan in the third quarter increased by 24.84% year-on-year
Glonghui, October 26丨Haichen Pharmaceutical (300584.SZ) announced its report for the third quarter of 2023. Operating revenue for the reporting period was 116 million yuan, up 4.27% year on year; net profit attributable to shareholders of listed companies was 2.947,500 yuan, up 24.84% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2,585.95 million yuan, up 10.98% year on year; basic earnings per share were 0.0246 yuan.
Some pharmacies are out of stock of azithromycin for children
Glonghui, October 18 | According to Sino-Singapore Finance, recently, the incidence of respiratory infectious diseases such as mycoplasma pneumonia in children has risen, and the increase in demand for antibiotics such as azithromycin has attracted attention. Recently, the reporter changed the location of different cities and searched on various e-commerce platforms and found that drugs such as azithromycin, clarithromycin, and roxithromycin are still available for purchase. On the offline side, some offline pharmacies are temporarily out of stock for children. Taking Beijing as an example, the reporter visited a number of offline pharmacies in Beijing to inquire about the availability of azithromycin. Some staff said that the supply of drugs in stores is currently guaranteed, while some pharmacies also claim that azithromycin for adults is in stock.
Haichen Pharmaceutical (300584.SZ): The lithium battery electrolyte additive project is progressing normally
Glonghui September 27丨Haichen Pharmaceutical (300584.SZ) investor relations activity record table shows that the company's lithium battery electrolyte additive project is progressing normally, and trial production is expected to begin by the end of 2023.
Haichen Pharmaceutical (300584.SZ): No diet drug-related products
Glonghui September 22丨Haichen Pharmaceutical (300584.SZ) said on an interactive platform that the company has no diet drug-related products.
Haichen Pharmaceutical (300584.SZ): Controlling shareholders, actual controllers, and directors and supervisors promise not to reduce their holdings of the company's shares
Glonghui, September 14, 丨 Haichen Pharmaceutical (300584.SZ) announced that it has recently received a “Letter of Commitment not to reduce company shares within the next six months” from the company's controlling shareholder, actual controller, Mr. Cao Yuping, Ms. Jiang Xiaoqun, and other directors and supervisors holding the company's shares (Supervisor Ms. Luo Yan, Deputy General Manager Mr. Liu Weicheng). The company's controlling shareholders, actual controllers, and other directors and supervisors holding the company's shares voluntarily promise not to reduce their holdings within six months from signing the letter of commitment (that is, September 14, 2023 to March 13, 2024) Shares , including that portion of the commitment period
Haichen Pharmaceutical (300584.SZ) released first-half results, net profit of 19.474,900 yuan, an increase of 9.89%
Haichen Pharmaceutical (300584.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Company Q&A | Haichen Pharmaceutical: The company has no brain-computer interface products or solutions
Gelonghui, June 5 丨 Some investors asked Haichen Pharmaceutical on the interactive platform: Does your company have any brain-computer interface products or solutions? Haichen Pharmaceutical: Our company has no brain-computer interface products or solutions.
Cao Yuping, one of the actual controllers of Haichen Pharmaceutical (300584.SZ), released the pledge of 6.8 million shares
According to the Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) announced that the company received a notice from the controlling shareholder, one of the actual controllers, and chairman Cao Yuping, who learned that it would go through the pledge removal procedure for some of the company's shares, and that it has now released the pledge of 6.8 million shares.
Haichen Pharmaceutical (300584.SZ): Net profit in the first quarter fell 3.23% to 12.219,800 yuan
Gelonghui, April 24, 丨 Haichen Pharmaceutical (300584.SZ) announced its report for the first quarter of 2023. Revenue for the reporting period was 117 million yuan, a decrease of 22.18% over the previous year; net profit attributable to shareholders of listed companies was 12.21,800 yuan, a decrease of 3.23% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,5061 million yuan, an increase of 4.08% over the previous year; basic earnings per share were 0.1018 yuan.
Haichen Pharmaceutical (300584.SZ) announced its 2022 annual results, with net profit of 32.4489 million yuan, a decrease of 88.65%
According to the Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its 2022 annual report. During the reporting period, the company achieved operating income of 526 million yuan, a year-on-year decrease of 8.97%. Net profit attributable to shareholders of listed companies was 32.448,900 yuan, a year-on-year decrease of 88.65%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was achieved of 31,4584 million yuan, an increase of 30.79% over the previous year. Basic earnings per share were $0.2,704.
No Data